More than one-third of adults in the United States have metabolic syndrome (dysfunctional metabolism), a cluster of conditions that significantly raise a person’s risk...
Researchers at the Case Western Reserve School of Medicine have found that, when compared to seven other anti-diabetic drugs, semaglutide, a popular diabetes and...
The eagerly awaited A4M October Symposium is set to return to the luxurious Encore Boston between October 24-26, 2024. An exceptional and diverse agenda...
In the ever-evolving landscape of medical science, certain discoveries stand out not just for their initial impact, but for their ability to continually reveal new and unexpected benefits. Glucagon-like peptide-1 receptor agonists (GLP-1 agonists) stand as prime examples of such pharmaceutical revelations. Initially developed for diabetes management and then repurposed for obesity treatment, these versatile compounds are now capturing attention for their potential cognitive benefits, further expanding their already impressive repertoire of clinical applications.
BMI and weight don’t necessarily predict the total picture of health. Yet those in med school are still taught to tell patients to lose weight because the training focuses on weight and BMI exacerbating anti-obesity bias and increasing the risk of eating disorders. However, that same training doesn’t really provide the medical students adequate education on how to encourage healthier eating habits or what good nutrition means; at least according to a study from the University of Georgia published in Medical Science Educator.
Earlier this month, the first class of pioneering soon-to-be weight management experts gathered for the inaugural Clinical Weight Management Certification Program in Scottsdale, Arizona. This immersive experience was filled with insightful lectures, thought-provoking discussions, and engaging collaborative learning opportunities that left participants empowered and equipped with the critical knowledge and skills needed to navigate the complex weight management landscape. Amid the current obesity epidemic and craze surrounding Ozempic and similar “miracle” weight loss drugs, acquiring expertise in this field has become increasingly vital for healthcare providers across disciplines.
As the U.S. obesity prevalence surpasses 40% in the adult population, the need for effective, long-term weight management solutions has become a national health imperative. In the quest for reliable weight loss interventions, scientists are working tirelessly to address this metabolic health crisis. Amid this challenge, a new star has risen in the form of semaglutide and similar GLP-1 agonists. While Ozempic and its counterparts have shown remarkable results in aiding weight loss, captured headlines, and ignited hopes, they are just one facet of the rapidly evolving landscape of obesity medicine innovation.
Behind the scenes, emerging research is shedding light on the complex interplay between the body, brain, biological systems, and dietary patterns. Recent scientific discoveries, such as the surprising impact of loneliness on eating habits and the intriguing influence of a father’s diet on offspring health, underscore the importance of an integrated and multifaceted approach to weight management. This growing body of research is challenging long-held beliefs and opening up new avenues for prevention and treatment, laying the foundation for a more informed and promising future in weight management.
Weight loss that is caused by a common diabetes drug has been tied to an ‘anti-hunger’ molecule in a Stanford Medicine study published in Nature Metabolism, finding that the commonly prescribed drug stimulates the production of lac-phe which is a molecule that is found in abundance after exercising.
